Syndax Pharmaceuticals, Inc. (SNDX)
NASDAQ: SNDX · Real-Time Price · USD
16.38
+0.39 (2.44%)
Feb 21, 2025, 4:00 PM EST - Market closed
Syndax Pharmaceuticals Stock Forecast
Stock Price Forecast
The 10 analysts with 12-month price forecasts for Syndax Pharmaceuticals stock have an average target of 36.2, with a low estimate of 16 and a high estimate of 51. The average target predicts an increase of 121.00% from the current stock price of 16.38.
Analyst Consensus: Strong Buy
* Price targets were last updated on Jan 8, 2025.
Analyst Ratings
The average analyst rating for Syndax Pharmaceuticals stock from 10 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Sep '24 | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 7 | 7 | 8 | 8 | 7 | 7 |
| Buy | 3 | 2 | 2 | 2 | 2 | 2 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 11 | 10 | 11 | 11 | 10 | 10 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Scotiabank | Scotiabank | Hold Maintains $18 → $16 | Hold | Maintains | $18 → $16 | -2.32% | Jan 8, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $51 | Strong Buy | Reiterates | $51 | +211.36% | Dec 10, 2024 |
| JP Morgan | JP Morgan | Buy Maintains $33 → $38 | Buy | Maintains | $33 → $38 | +131.99% | Nov 21, 2024 |
| Citigroup | Citigroup | Strong Buy Maintains $37 → $45 | Strong Buy | Maintains | $37 → $45 | +174.73% | Nov 19, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $49 → $51 | Strong Buy | Maintains | $49 → $51 | +211.36% | Nov 18, 2024 |
Financial Forecast
Revenue This Year
98.30M
Revenue Next Year
92.20M
from 98.30M
Decreased by -6.20%
EPS This Year
-3.25
from -2.98
EPS Next Year
-3.98
from -3.25
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 436.8M | 256.4M | 278.3M | |||
| Avg | 98.3M | 92.2M | 201.3M | |||
| Low | 15.7M | 45.7M | 139.3M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | 160.9% | 201.9% | |||
| Avg | - | -6.2% | 118.3% | |||
| Low | - | -53.5% | 51.0% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 0.91 | -1.77 | -1.74 | |||
| Avg | -3.25 | -3.98 | -3.09 | |||
| Low | -3.83 | -4.88 | -3.84 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.